Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521569 · ClinicalTrials.gov registry record · Early Phase 1
Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 47
- Enrollment target
NCT04521569 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 47 participants.
The verdict
NCT04521569, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.
Interventions
- DRUG Placebo
- DRUG Regadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2024-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04521569
The ClinicalTrials.gov registry entry for NCT04521569 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04521569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04521569 about?
NCT04521569 is a clinical study titled "Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System". The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.
What is the current status of trial NCT04521569?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 47 participants. The study started on 2020-06-22. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT04521569?
The interventions under investigation include: Placebo (DRUG), Regadenoson (DRUG).
Who is sponsoring clinical trial NCT04521569?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.